115TH CONGRESS 1ST SESSION H.R. 3382

To amend the Public Health Service Act to better address substance use and substance use disorders among young people.

IN THE HOUSE OF REPRESENTATIVES

JULY 25, 2017

Ms. CLARK of Massachusetts (for herself and Mr. BUCSHON) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to better address substance use and substance use disorders among young people.

1 Be it enacted by the Senate and House of Representa-

2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the "Youth Opioid Use5 Treatment Help Act of 2017" or the "YOUTH Act".

6 SEC. 2. REAUTHORIZATION OF SUBSTANCE ABUSE TREAT-

7 MENT SERVICES FOR CHILDREN, ADOLES8 CENTS, AND YOUNG ADULTS.

9 Section 514 of the Public Health Service Act (42
10 U.S.C. 290bb-7) is amended—

1	(1) in the section heading, by striking "CHIL-
2	DREN AND ADOLESCENTS " and inserting "CHIL-
3	DREN, ADOLESCENTS, AND YOUNG ADULTS";
4	(2) in subsection $(a)(2)$, by striking "children,
5	including" and inserting "children, adolescents, and
6	young adults, including"; and
7	(3) by striking "children and adolescents" each
8	place it appears and inserting "children, adolescents,
9	and young adults".
10	SEC. 3. ACCESS TO MEDICATION-ASSISTED TREATMENT
11	FOR ADOLESCENTS AND YOUNG ADULTS
12	DEMONSTRATION PROGRAM.
13	(a) IN GENERAL.—The Secretary of Health and
14	Human Services, acting through the Director of the Agen-
15	cy for Healthcare Research and Quality (in this section
16	referred to as the "Director"), shall award grants to eligi-
17	ble entities to establish demonstration programs to—
18	(1) expand access to medication-assisted treat-
19	ment for opioid use disorders among adolescents and
20	young adults;
21	(2) identify and test solutions for overcoming
22	barriers to implementation of medication-assisted
23	treatment for adolescents and young adults; or
24	(3) create and distribute resources on medica-
25	

for providers of health care to children, adolescents,
 and young adults.

3 (b) ELIGIBLE ENTITIES.—To be eligible to receive a
4 grant under subsection (a), an entity shall—

5 (1) be a State, political subdivision of a State, 6 Indian tribe, or tribal organization, professional fam-7 ily medicine provider organization, professional pedi-8 atric provider organization or other organization 9 representing providers of health care to children, 10 adolescents, and young adults, professional addiction 11 medicine provider organization, hospital, an institu-12 tion of higher education, or other appropriate public 13 or nonprofit institution; and

14 (2) certify that it is in compliance with all ap-15 plicable registration and licensing requirements.

(c) APPLICATION.—To seek a grant under this section, an entity shall submit to the Director an application
at such time, in such manner, and containing such information as the Director may require.

(d) DURATION.—An eligible entity may receive funds
under this section to carry out a demonstration program
described in this section for a period of not greater than
3 years. After the first year for which funding is provided
to an eligible entity for a demonstration program, funding
may be provided under this section for a subsequent year

for such program only upon review of such program by
 the Director and approval by the Director of such subse quent year of funding.

4 (e) Reports.—

5 (1) BY GRANT RECIPIENTS.—Each eligible enti-6 ty awarded a grant under this section for a dem-7 onstration program shall submit to the Director 8 progress reports on such demonstration program at 9 such times, in such manner, and containing such in-10 formation as the Director may require.

(2) BY DIRECTOR.—Not later than one year
after the date on which all demonstration programs
funded under this section have been completed, the
Director shall submit to the Committee on Health,
Education, Labor, and Pensions of the Senate, and
the Committee on Energy and Commerce of the
House of Representatives a report that—

18 (A) describes the availability of medication19 assisted treatment for adolescents and young
20 adults with opioid use disorders in the United
21 States, including barriers to such treatment;

(B) describes the specific demonstration
programs carried out pursuant to this section;
(C) evaluates the effectiveness of such programs;

1	(D) evaluates any unintended consequences
2	of such programs; and
3	(E) provides recommendations for ensuring
4	that medication-assisted treatment is accessible
5	to adolescents and young adults with opioid use
6	disorders.
7	(f) DEFINITIONS.—In this section:
8	(1) The phrase "adolescents and young adults"
9	means individuals who have attained 10 years of age
10	and not yet attained 26 years of age.
11	(2) The term "medication-assisted treatment"
12	means the combination of pharmacological treat-
13	ments approved by the Food and Drug Administra-
14	tion, and counseling and behavioral therapies, for
15	the treatment of substance use disorders.
16	(3) The term "opioid use disorder" means a
17	problematic pattern of opioid use leading to clinically
18	significant impairment or distress occurring within a
19	12-month period.
20	(4) The term "pediatric health care provider"
21	means a provider of health care to individuals who
22	have attained 10 years of age and not yet attained
23	26 years of age.
24	(5) The term "professional family medicine pro-
25	vider organization" means a national organization

5

whose members consist primarily of family medicine
 providers.

3 (6) The term "professional pediatric provider
4 organization" means a national organization whose
5 members consist primarily of pediatric health care
6 providers.

7 (g) AUTHORIZATION OF APPROPRIATIONS.—There is
8 authorized to be appropriated \$5,000,000 to carry out this
9 section.

 \bigcirc